BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Drug Information Association and National Organization for Rare Disorders Hold 1st US Conference on Rare Diseases and Orphan


10/7/2011 2:02:11 PM

WASHINGTON, DC-OCTOBER 7, 2011--DIA and the National Organization for Rare Disorders (NORD) today announced the release of a new report detailing how flexible the Food and Drug Administration is in approving pharmaceuticals for rare diseases. The report will be released during the first US Conference on Rare Diseases and Orphan Products from October 11-13.

The following panel of experts will be present to discuss the report:

• Frank J. Sasinowski, Chair, NORD, and author of the report

• Janet Woodcock, Director, Center for Drug Evaluation and Research, FDA

• Christopher Paul-Milne, Associate Director, Tufts Center for the Study of Drug Development

• David P. Meeker, COO, Genzyme Corporation

A rare disease is defined Orphan Drug Act of 1983 as a disease or condition that affects fewer than 200,000 persons in the United States.

This conference will also feature panel discussions with pharmaceutical and healthcare industry leaders, patient advocacy groups and federal regulators, including: Francis S. Collins, Director, NIH; Fred Hassan, Warburg Pincus, Chairman, Bausch + Lomb; Jeffrey Shuren, Director, Center for Devices and Radiological Health, FDA; John F. Crowley, Chairman and CEO, Amicus Therapeutics; and Michael J. Astrue, Commissioner, Social Security Administration.

RSVP by October 10 to Joe Krasowski at joe.krasowski@diahome.org.

ABOUT DIA

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China.

ABOUT NORD

NORD is a nonprofit organization representing all patients and families affected by rare diseases in the U.S. It was established in 1983 by rare disease patient organization leaders who had worked together on behalf of enactment of the Orphan Drug Act. Today, NORD provides programs and services that include advocacy, education of patients and medical professionals, support for research, and patient assistance programs to help patients access life-saving therapies.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES